AstraZeneca delivered another runner-up finish for the second consecutive year. The company’s profile reflects peaks at both ends of the pipeline, with 1st place in both commercial and research and 17th place in clinical. This highlights AstraZeneca’s strength in discovery and market execution, with clinical operations remaining the key opportunity to close the loop from hypothesis to evidence.

Over the past year, AstraZeneca invested heavily in AI partnerships aimed at accelerating cancer drug development and advancing early diagnostics. On the research side, MILTON, an AI system trained on large- scale health records, was developed to predict over 1,000 diseases before diagnosis, supporting earlier risk detection.

In digital pathology, the company partnered with Lunit and Mindpeak to develop AI-powered risk assessment and image analysis tools for NSCLC, improving diagnostic precision and patient stratification. In collaboration with Aptar Digital Health, AstraZeneca also advanced connected inhaler solutions that link device telemetry with adherence and clinical outcomes, supporting more personalized respiratory care.

At the enterprise level, AstraZeneca advanced its Development Assistant, an AI-enabled multi-agent governance-cleared system, from concept to a production-ready MVP. The company also scaled workforce AI upskilling programs to drive adoption across global functions.

In clinical access, AstraZeneca advanced its partnership with Walgreens and Evinova to bring clinical trials closer to underrepresented communities. The AIRE Mobile Unit, integrated with Walgreens retail sites, made more than 500 stops across Los Angeles and San Antonio, reaching over 15,000 people in its first year. The initiative has since grown into a 20-site, eight-state network, with Walgreens referrals 20% more likely to enroll than other recruitment sources.

To reinforce long-term scale, AstraZeneca announced multibillion-dollar investments in new R&D and manufacturing hubs that integrate analytics and automation. It also signed a data partnership with Tempus, valued at up to $200 million dollars, to accelerate model-ready clinical genomics and decision support.

In 2025, AstraZeneca sustained its position as a leading platform innovator, extending AI and data capabilities across discovery, development, and delivery to close the evidence loop between science and real-world outcomes.